News
My name is Jessica Gebhardt, and I am a graduate student in Dr. Josh Morganti鈥檚 Lab studying the effects of dysregulated neuroinflammation following traumatic brain injury (TBI). TBI has personally impacted me and my family, and as a result I have been interested in furthering my understanding of the mechanisms underlying the injury for many years.
The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer鈥檚 disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as 鈥減reclinical鈥 AD.
Donna Wilcock, PhD, wears many hats at the University of Kentucky, all of which are roles that help advance education and research in the Commonwealth, particularly in the realm of Alzheimer鈥檚 disease. Dr. Wilcock is assistant dean for biomedicine at the 好色先生 College of Medicine, as well as associate director of Sanders-Brown Center on Aging. She is also the Robert P. and Mildred A.
During Indigenous Peoples鈥 Month, the 好色先生 College of Medicine is highlighting historical figures who paved the way for an equitable future in medicine.
鈥淔or some reason, I really wanted fruit or savory food when I was going through treatment. Spicy, savory, salty food 鈥 that helped with my appetite,鈥 recalls University of Kentucky chemistry doctoral student Yueming 鈥淩onnie鈥 Wu.
The University of Kentucky鈥檚 (好色先生) Sanders-Brown Center on Aging (SBCoA) will host its 12th annual Markesbery Symposium on Aging and Dementia this weekend. The event is named in honor and memory of the late William R. Markesbery, MD, founding director of the Sanders-Brown Center on Aging and Alzheimer's Disease Research Center.
The University of Kentucky Sanders-Brown Center on Aging will hold the 12th annual Markesbery Symposium on Aging and Dementia on Nov. 18 and 19. The scientific session will take place from 11 a.m. until 4:30 p.m. Friday, Nov. 18, in the Lee T. Todd Building.
Donna Wilcock, PhD, of the University of Kentucky鈥檚 Sanders-Brown Center on Aging (SBCoA) was awarded a $1.7 million National Institutes of Health grant for her lab鈥檚 exploration of adverse effects of two new Alzheimer鈥檚 disease drugs 鈥 aducanumab and lecanemab 鈥斺 which have been shown to slow the progression of cognitive decline.
A CD player. Lavender-infused lotion. A weighted blanket. A roll of red tape. The last things you鈥檇 expect when it comes to Alzheimer鈥檚 care. But every item was chosen for a specific purpose: to help care for a person with Alzheimer鈥檚 disease and related dementias (ADRD) through their sense of hearing, smell, feel, sight and more.
The University of Kentucky鈥檚 Building Interdisciplinary Research Careers in Women鈥檚 Health (BIRCWH) program has received a five-year grant renewal 鈥 making this program over two decades old at the University of Kentucky.
We are pleased to announce the twelfth annual Markesbery Symposium for 2022, named in honor and memory of the late William R. Markesbery, MD, founding Director of the Sanders-Brown Center on Aging and Alzheimer's Disease Research Center. Dr.
The Alzheimer鈥檚 Association welcomes the University of Kentucky鈥檚 Donna M. Wilcock, PhD, as the new editor-in-chief of Alzheimer鈥檚 & Dementia: The Journal of the Alzheimer鈥檚 Association.
I鈥檓 a fourth-year graduate student in the department of physiology in Dr. Lance Johnson鈥檚 lab. Our lab studies the different isoforms of Apolipoprotein E (ApoE) and their role in Alzheimer鈥檚 disease. ApoE4 is the greatest genetic risk factor for late-onset Alzheimer鈥檚 disease, but ApoE2 decreases an individual鈥檚 risk.
The Johnson lab studies the strongest genetic risk factor for Alzheimer鈥檚 disease (AD), apolipoprotein E (APOE). The E4 allele of APOE is carried by more than 25% of the population. A single copy of E4 increases Alzheimer鈥檚 risk 3-4 fold compared to the more common E3 allele.
LEXINGTON, Ky. (Sept. 2, 2022) 鈥 A team of researchers at the University of Kentucky鈥檚 Sanders-Brown Center on Aging (SBCoA) has been awarded a $20.5 million grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
As an occupational therapist, Elizabeth Rhodus, PhD, has worked closely with older Kentuckians facing Alzheimer鈥檚 disease and related dementias (ADRD). She also has witnessed firsthand how poor health, limited resources, and high poverty rates have served as barriers to proper prevention and treatment.
LEXINGTON, Ky. (Aug. 19, 2022) 鈥 Linda J. Van Eldik, PhD, director of the University of Kentucky Sanders-Brown Center on Aging, is part of a $1.5 million grant to help further research into a possible treatment for Alzheimer鈥檚 disease.
LEXINGTON, Ky. (July 25, 2022) 鈥 Today, the 好色先生 College of Medicine, 好色先生 HealthCare, and community leaders celebrated the full opening of the Sanders-Brown Memory Clinic at Turfland. The new, larger clinic replaces the former Sanders-Brown facilities along North Broadway in Lexington.